The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) who purchased securities between March 17, 2022 and June 20, 2023. The action, which was filed in the United States District Court for the District of Massachusetts, alleges that the Company violated federal securities laws.
In particular, the Aldeyra lawsuit alleges that (i) the ADX-2191 new drug application ("NDA") did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Shareholders have until September 29, 2023 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
To learn more and keep informed, complete this form >